logo
Plus   Neg
Share
Email

Merck: FDA Grants Priority Review To SBLA For Keytruda Monotherapy

Drug maker Merck & Co. Inc. (MRK) said Tuesday that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental Biologics License Application or sBLA for Keytruda, Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with advanced small cell lung cancer (SCLC) whose disease has progressed after two or more lines of prior therapy.

This sBLA, which is seeking accelerated approval for this new indication, is based on data from the SCLC cohorts of the Phase 2 KEYNOTE-158 and Phase 1b KEYNOTE-028 trials. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 17, 2019, Merck noted.

"There is a significant need for new treatment options for small cell lung cancer, which has a five-year survival rate of only six percent overall. KEYTRUDA has already been established as an important treatment option for many patients with advanced non-small cell lung cancer and this acceptance provides an opportunity to potentially benefit even more patients," said Dr. Jonathan Cheng, vice president, oncology clinical research, Merck Research Laboratories.

Merck noted that the acceptance marks the first U.S. application for Keytruda in SCLC and demonstrates its commitment to bringing forward new treatment options for patients with historically difficult-to-treat cancers, like SCLC.

As part of Merck's broad clinical development in lung cancer, Keytruda is being studied in combination with chemotherapy in the ongoing Phase 3 KEYNOTE-604 study in patients with newly diagnosed extensive stage SCLC.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of... Chipmaker Intel Corp. said it plans to exit the 5G smartphone modem business, with the announcement coming just hours after Apple Inc. and Qualcomm Inc. said they have settled their royalty dispute. The settlement includes a payment from Apple to Qualcomm, but no details were disclosed about the payment or fees. Qualcomm's shares are gaining more than 14 percent in Wednesday's trading session.
Follow RTT